• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Xofigo (radium Ra 223 dichloride)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Xofigo (radium Ra 223 dichloride)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Xofigo (radium Ra 223 dichloride), an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug.

    Xofigo is specifically indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

    Xofigo is supplied as a solution for intravenous administration. The recommended dose is s 50 kBq (1.35 microcurie) per kg body weight, given at 4 week intervals for 6 injections.

    Clinical Results

    FDA Approval
    The FDA approval of Xofigo was based on a double-blind, randomized, placebo-controlled phase III clinical trial of 809 subjects with castration-resistant prostate cancer with symptomatic bone metastases. Subjects with visceral metastases and malignant lymphadenopathy exceeding 3 cm were excluded. The subjects received Xofigo 50 kBq (1.35 microcurie)/kg intravenously every 4 weeks for 6 cycles plus best standard of care or matching placebo plus best standard of care. The primary efficacy endpoint was overall survival. The pre-specified interim analysis of overall survival revealed a statistically significant improvement in patients receiving Xofigoplus best standard of care compared with patients receiving placebo plus best standard of care. An exploratory updated overall survival analysis performed before patient crossover with an additional 214 events resulted in findings consistent with the interim analysis. At the interim analysis the median survival was 14 months versus 11.2 months, respectively. At the updated analysis the median survival was 14.9 versus 11.3 months, respectively.

    Side Effects

    Adverse events associated with the use of Xofigo may include, but are not limited to, the following:

    • nausea
    • diarrhea
    • vomiting
    • peripheral edema

    Mechanism of Action

    Xofigo (radium Ra 223 dichloride), an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium Ra 223 dichloride, which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The high linear energy transfer of alpha emitters leads to a high frequency of double-strand DNA breaks in adjacent cells, resulting in an anti-tumor effect on bone metastases. The alpha particle range from radium-223 dichloride is less than 100 micrometers which limits damage to the surrounding normal tissue.

    Additional Information

    For additional information regarding Xofigo or prostate cancer and bone metastases, please visit the Bayer web page.

    Approval Date: 2013-05-01
    Company Name: Bayer Healthcare Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing